Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label multicenter study of peginterferon alfacon-2 injection for hepatic epithelioid hemangioendothelioma
CTR20243240Phase 2Active
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfacon-2 in Hepatic epithelioid hemangioendothelioma (HEHE), sponsored by Beijing Kawin Technology Share-Holding Co., Ltd.. Started Aug 2024; status: active.
02
Drugs
peginterferon alfacon-2
03
Conditions
Hepatic epithelioid hemangioendothelioma (HEHE)
Beyond the preview
Go deeper on CTR20243240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243240.